

Freedom of Information Request: FOI 0326 2019/20

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

Queen Elizabeth Hospital Birmingham

1.
 - a. Does your trust treat advanced breast cancer? Yes
 - b. If none, where are your patients referred? Not Applicable

Question 2

In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;

HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]	
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]	
HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]	
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease	
Not Known	

We do not record the HR/HER information requested above, but we can tell you:

Total breast cancer patients recorded as Stage IV in last 3 months = 0

Total breast cancer patients (any stage) in last 3 months = 356

Question 3

In the past 3 months, how many breast cancer patients were treated with:

- Abemaciclib (Verzenios) + aromatase inhibitor ***
- Abemaciclib (Verzenios) + Fulvestrant (Faslodex)**
- Alpelisib (Piqray) + Fulvestrant (Faslodex)**
- Atezolizumab (Tecentriq)****
- Bevacizumab (Avastin)**
- Eribulin (Halaven)**
- Everolimus (Afinitor) + Exemestane**
- Fulvestrant (Faslodex) as a single agent**
- Gemcitabine + paclitaxel**
- Lapatinib (Tyverb)**
- Neratinib (Nerlynx)**
- Olaparib (Lynparza)**

Palbociclib (Ibrance) + aromatase inhibitor*
Pertuzumab (Perjeta) + trastuzumab + docetaxel
Ribociclib (Kisqali) + aromatase inhibitor*
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
Talazoparib (Talzenna)
Trastuzumab + paclitaxel
Trastuzumab as a single agent
Trastuzumab emtansine (Kadcyla)

Other active systemic anti-cancer therapy **

***aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole**

****eg. docetaxel, vinorelbine or capecitabine as a single agent**

With the above combinations, we have included all combinations of chemo drugs below

Regimen_name	Drug/Diluent	Total
Palbociclib	NULL	7
FEC100 ± SC Trastuzumab (adjuvant/neoadj)	Akynzeo (Netupitant 300mg / Palonosetron 0.5mg)	5
FEC100 ± Trastuzumab (adjuvant/neoadj)	Akynzeo (Netupitant 300mg / Palonosetron 0.5mg)	2
FEC75 ± SC Trastuzumab	Akynzeo (Netupitant 300mg / Palonosetron 0.5mg)	2
CMF (classical iv cyclo) ± Trastuzumab	Calcium Folate	1
Paclitaxel and Carboplatin weekly	Chlorphenamine	1
CMF (classical iv cyclo) ± Trastuzumab	Cyclophosphamide	1
Docetaxel & Cyclophosphamide ± Trastuzumab and Pertuzumab	Cyclophosphamide	1
FEC100 ± SC Trastuzumab (adjuvant/neoadj)	Cyclophosphamide	5
FEC100 ± Trastuzumab (adjuvant/neoadj)	Cyclophosphamide	2
FEC75 ± SC Trastuzumab	Cyclophosphamide	2
CMF (classical iv cyclo) ± Trastuzumab	Dexamethasone	1
Eribulin	Dexamethasone	1
FEC100 ± SC Trastuzumab (adjuvant/neoadj)	Dexamethasone	5
FEC100 ± Trastuzumab (adjuvant/neoadj)	Dexamethasone	2
FEC75 ± SC Trastuzumab	Dexamethasone	2
Paclitaxel and Carboplatin weekly	Dexamethasone	1
FEC100 ± SC Trastuzumab (adjuvant/neoadj)	Epirubicin	5
FEC100 ± Trastuzumab (adjuvant/neoadj)	Epirubicin	2
FEC75 ± SC Trastuzumab	Epirubicin	2
Eribulin	Eribulin	1
CMF (classical iv cyclo) ± Trastuzumab	Fluorouracil	1
FEC100 ± SC Trastuzumab (adjuvant/neoadj)	Fluorouracil	5
FEC100 ± Trastuzumab (adjuvant/neoadj)	Fluorouracil	2
FEC75 ± SC Trastuzumab	Fluorouracil	2
Docetaxel/Carboplatin ± Trastuzumab/Pertuzumab	Glucose (5%)	4
Paclitaxel and Carboplatin weekly	Glucose (5%)	1

CMF (classical iv cyclo) ± Trastuzumab	Methotrexate	1
CMF (classical iv cyclo) ± Trastuzumab	Ondansetron	1
Docetaxel & Cyclophosphamide ± Trastuzumab and Pertuzumab	Ondansetron	1
Docetaxel (Single agent) ± Trastuzumab	Ondansetron	2
Docetaxel/Carboplatin ± Trastuzumab/Pertuzumab	Ondansetron	4
Eribulin	Ondansetron	1
Paclitaxel and Carboplatin weekly	Ondansetron	1
Pertuzumab, Trastuzumab and Docetaxel	Ondansetron	3
Paclitaxel and Carboplatin weekly	Ranitidine	1
Capecitabine (Breast) ± Trastuzumab	Sodium Chloride	2
CMF (classical iv cyclo) ± Trastuzumab	Sodium Chloride	1
Docetaxel & Cyclophosphamide ± Trastuzumab and Pertuzumab	Sodium Chloride	1
Docetaxel (Single agent) ± Trastuzumab	Sodium Chloride	2
Docetaxel/Carboplatin ± Trastuzumab/Pertuzumab	Sodium Chloride	4
FEC100 ± SC Trastuzumab (adjuvant/neoadj)	Sodium Chloride	5
FEC100 ± Trastuzumab (adjuvant/neoadj)	Sodium Chloride	2
FEC75 ± SC Trastuzumab	Sodium Chloride	2
Paclitaxel and Carboplatin weekly	Sodium Chloride	1
Pembrolizumab flat dose	Sodium Chloride	1
Pertuzumab, Trastuzumab and Docetaxel	Sodium Chloride	3
FEC100 ± SC Trastuzumab (adjuvant/neoadj)	Trastuzumab	5
FEC75 ± SC Trastuzumab	Trastuzumab	2
Trastuzumab adjuvant (3 weekly) subcutaneous	Trastuzumab	4
Trastuzumab metastatic (Single agent 3w) subcutaneous	Trastuzumab	1

Heartlands, Good Hope and Solihull Hospitals

1.

- a. Does your trust treat advanced breast cancer? Yes
- b. If none, where are your patients referred? Not Applicable

Question 2

In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;

We do not record the HR/HER information requested below

HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]	
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]	

HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]	
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease	
Not Known	

Question 3

In the past 3 months, how many breast cancer patients were treated with:

Abemaciclib (Verzenios) + aromatase inhibitor * = 2
 Abemaciclib (Verzenios) + Fulvestrant (Faslodex) = 11
 Alpelisib (Piqray) + Fulvestrant (Faslodex) = 0
 Atezolizumab (Tecentriq)** = 1
 Bevacizumab (Avastin) = 0
 Eribulin (Halaven) = 13
 Everolimus (Afinitor) + Exemestane = 2
 Fulvestrant (Faslodex) as a single agent = 0
 Gemcitabine + paclitaxel = 0
 Lapatinib (Tyverb) = 0
 Neratinib (Nerlynx) = 0
 Olaparib (Lynparza) = 0

Palbociclib (Ibrance) + aromatase inhibitor* = 36
 Pertuzumab (Perjeta) + trastuzumab + docetaxel = 12
 Ribociclib (Kisqali) + aromatase inhibitor* = 3
 Ribociclib (Kisqali) + Fulvestrant (Faslodex) = 0
 Talazoparib (Talzenna) = 0
 Trastuzumab + paclitaxel = 1
 Trastuzumab as a single agent = 56
 Trastuzumab emtansine (Kadcyla) = 10

NB: Figures above are numbers of patients, not hospital attendances, and refer to the period 01/06/2019 to 31/08/2019 inclusive.

Other active systemic anti-cancer therapy ** 120

NB: Figures above are numbers of patients, not hospital attendances.

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

**eg. docetaxel, vinorelbine or capecitabine as a single agent